These strategies are anticipated to harness the neurogenic and cognitive potential of pharmacological interventions targeting the NPY1R and Ketamine pathways, offering significant promise for enhancing patient outcomes in neurodegenerative disease contexts. This evidence concerns the gene NPY1R and neurodegenerative disease.